Combined hyperfractionated radiotherapy and protracted infusion chemotherapy in bladder cancer for organ preservation

Clinica Terapeutica

Volumn 149, Issue 3, 1998, Pages 183-189

  Saracino, B ^a   Arcangeli, G ^a   Mecozzi, A ^b   Tirindelli Danesi, D ^c   Cruciani, E ^b   Altavista, P ^c   Giannarelli, D ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Fatebenefratelli Hospital   (Italy)

^c ENEA C R CASACCIA   (Italy)

Author keywords

5 fluorouracil; Bladder cancer; Cisplatin; Hyperfractionated radiotherapy; Organ sparing; Protracted infusion chemotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORGAN PRESERVATION; RADIATION DOSE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; PARTICLE ACCELERATORS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0031763064     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Van der Werf-Messing B: Carcinoma of the urinary bladder T3 Nx MO treated by preoperative irradiation followed by simple cystectomy. Int J Radiat Oncol Biol Phys 8:1849-1855, 1982
2. Whitmore WF, Batata WA, Hilaris BS, et al.: A comparative study of two preoperative radiation regimens with cystectomy for bladder cancer. Cancer 40:1077-1086, 1977
3. Herr HW: Preoperative irradiation with and without chemotherapy as adjunct to radical cystectomy. Urology 25:127-134, 1985
4. Bloom HJG, Hendry WF, Wallace DM, et al.: Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 54:136-151, 1982
5. Wizenberg MJ: Invasive bladder cancer: Definitive irradiation and salvage cystectomy. Semin Oncol 6:229-235, 1979
6. Blandy JP, England HR, Evans SJW, et al.: T3 bladder cancer: The case for salvage cystectomy. Br J Urol 52:506-510, 1980
7. Blandy JP, Jenkins BJ, Fowler CG, et al.: Radical radiotherapy and salvage cystectomy for T2/T3 cancer of the bladder. Progress in Clinical and Biological Research 260:447-451, 1988
8. DeWeerd JH, Colby MY, Myers RP, et al.: Cystectomy after radiotherapeutic ablation of invasive transitional cell cancer. J Urol 118:260-261, 1977
9. Hussey L and Chan RC: Patterns of failure in patients treated by radiotherapy for genitourinary tumors. Cancer Treatment Symp 2:51-58, 1983
10. Stemberg CN, Yagoda A, Scher HI, t al.: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139:461-469, 1988
11. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 60:574-585, 1987
12. Scher HI, Yagoda A, Herr HW, et al.: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 139: 470-474, 1988
13. Harker WA, Meyers FJ, Freiha FS, et al.: Cisplatin, methotrexate and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group study. J Clin Oncol 3:1463-1470, 1985
14. Vogelzang NJ, Moormeier JA, Awan AM, et al.: Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. J Urol 149: 753-758, 1993
15. Dreicer R, Kollmorgen TA, Smith RF, et al.: Neoadjuvant cisplatin, methotrexate and vinblastin for muscle invasive bladder cancer: long-term follow-up. J Urol 150: 849-853, 1993
16. Jaske G, Frommhold H, Nedden DZ: Combined radiation and chemotherapy for locally advanced transitional cell carcinoma of the urinary bladder. Cancer 55:1659-1664, 1985
17. Dunst J, Sauer R, Schrott KM, et al.: Organ-sparing treatment of advanced bladder cancer: a 10- year experience. Int J Radiat Oncol Biol Phys 30 (2): 261-266, 1994
18. Tester W, Porter AT, Asbell S, et al.: Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25: 783-790, 1993
19. Tester W, Caplan R, Heaney J, et al.: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14 (1): 119-126, 1996
20. Kaufman DS, Shipley WU, Griffin PP, et al.: Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329:1377-1382, 1993
21. Richmond RC, Zimbrick JD, and Hykes DL: Radiation induced DNA damage and lethality in E. Coli as modified by an antitumor agent cis-dichlorodiamminoplatinum (II). Radiat Res 71:447-460, 1977
22. Begg AC, Van der Kolf PJ, Dewit L, et al.: Radiosensitization by cisplatin of RIFI tumor cells in vitro. Int J Radiat Oncol Biol Phys 50:871-884, 1986
23. Overgaard J. Selective enhancement of radiation response in C3H mammary carcinoma with cisplatin. Cancer Treat Rep 65:501-503, 1981
24. Dewit L. Combined treatment of radiation and cis diammine dichloroplatinum (II): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13:403-426, 1987
25. Rosenthal CJ, Rotman M, Choi K, et al.: Cisplatin by concurrent radiation in malignant tumors (A phase I-II study). In : Clinical Application of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy. Rosenthal CJ and Rotman M, eds., Plenum Press, New York and London, 1986, pp. 177-180.
26. Byfield JE, Calabro-Jones P, Klisak et al.: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-FU or ftorafur and x-rays. Int J Radiat Oncol Biol Phys 8: 1923-1933, 1982
27. Byfield JE: Theoretical basis and clinical applications of 5-FU as a radiosensitizer. In: Clinical Application of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy. Rosenthal CJ and Rotman M, eds., Plenum Press, New York and London, 1986, pp. 113-124
28. Byfield JE, Frankel SS, Sharp TR, et al.: Phase I pharmacologic study of 72-hours infused 5-FU and hyperfractionated cyclical radiation. Int Radiat Oncol Biol Phys 11:791-800, 1985
29. Lokich JJ, Ahlgren JD, Gullo JJ: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma : a Mid-Atlantic Oncology Program Study. J Clin Oncol 7:425-432, 1989
30. Rotman M, Aziz H, Porrazzo M, et al.: Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion. Int J Radiat Oncol Biol Physl 18: 1131-1137, 1990
31. Chretien Y, Mejean A, Durdux C, et al.: Infiltrating cancer of the bladder: Can radiochemotherapy be an alternative to cystectomy ? J Urol 102: 3-8, 1996 (suppl.1)
32. Keane TE, Gingrich JR, Rosner G, et al.: Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res 54: 475-481, 1994
33. Arcangeli G and Tirindelli Danesi D: Concomitant combination of radiotherapy and protracted venous infusion of anticancer drugs. Fifth International Meeting on Progress in Radio-Oncology, Salzburg; Monduzzi Ed., Int Proceedings Div 35-40, 1995
34. Hermanek P, Sobin LH, editors. UICC TNM Classification of malignant tumors. 4th ed. 2nd rev. Berlin : Springer-Verlag, 1992
35. Mantyla M, Kortekangas AE, Valavaara RA, et al.: Tumor regression during radiation treatment as a guide to prognosis. Br J Radiol 52:972-977, 1979
36. Suit H, Lindberg R, Fletcher GH: Prognostic significance of extent of tumor regression at completion of radiation therapy. Radiology 84:1100-1107, 1965